June 4, 2019- Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, today announces that the first patient has been dosed with its lead candidate, leriglitazone (MIN-102), in the phase 2 FRAMES clinical trial in Friedreich’s Ataxia.

| Read more |

Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, today announces that it has appointed Mr. Didier Le Normand as Group CFO as well as General Manager of its recently opened Belgian subsidiary.

| Read more |

FRAMES trial expected to initiate patient recruitment in upcoming weeks in Spain, Belgium and other European countries.
Two Key Opinion Leaders join Minoryx’s scientific advisory board.
In 2018 Minoryx closed a Series B funding round of €21.3M to expand the development of MIN-102 into new indications.

| Read more |

AELIX Therapeutics S.L. (“AELIX”), a clinical-stage biotechnology company specialized in the discovery and development of immunotherapies for HIV infection, today announces that it has entered into a clinical research collaboration with Gilead Sciences, Inc. (“Gilead”), a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need, to jointly evaluate proprietary investigational products in a strategic clinical study aimed at achieving a functional cure of HIV infection.

| Read more |